Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
3(75%)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

terminated375%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

NCT00445705
terminatedphase_2

Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain

NCT00441766
terminatedphase_2

Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

NCT00380783
completedphase_2

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

NCT00381719

Clinical Trials (4)

Showing 4 of 4 trials
NCT00445705Phase 2

Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

Terminated
NCT00441766Phase 2

Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain

Terminated
NCT00380783Phase 2

Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Terminated
NCT00381719Phase 2

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4